Some Research on Pregnant and Postpartum Women with HIV Is Presented at CROI, But More Trials Are Needed
Pregnant people who are living with or vulnerable to HIV need to be included in clinical trials in order to close our knowledge gaps.
HVTN 702 may not have proven an effective vaccine, but scientists still learned from the research.
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.
Undetectable equals untransmittable (U=U) has improved HIV prevention and tackled stigma, but there are still a few questions to answer.
"We don't need to spend another $140 million to find out how to retain people in care," activist David Barr writes. "We need to invest in the kinds of services people need so that they can use treatment easily and effectively."
The global increase in sexually transmitted infections was a major focus of the CROI 2019 meeting in Seattle, Washington.
TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.
Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.
Most people who could benefit from pre-exposure prophylaxis are not accessing it, the U.S. Centers for Disease Control and Prevention revealed at this year's Conference on Retroviruses and Opportunistic Infections.